Ariessence Pure PDGF+
Commercial- Indications
- Skin rejuvenation, Post-procedure healing
Company intelligence / Profile preview
Lynch Regenerative Medicine leverages a proven and patented rhPDGF technology already used in four FDA-approved products for orthopedics and oral surgery. The company recently acquired REGRANEX® Gel—an FDA-approved treatment for diabetic foot ulcers—and holds exclusive rights to use recombinant pure PDGF in soft tissue rejuvenation and regeneration. Clinical data from prior uses of this technology show significant improvements in wound healing rates[1][6][8].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Lynch Regenerative Medicine.